Trial intelligence / Profile preview

Acetazolamide on Postural Control at Altitude

NCT03536429Phase 4

Key facts

Status: Completed
Start: May 2018
Primary completion: Aug 2018
Countries: 1
Sponsor: University of Zurich
Modality: Small Molecules

Drugs: acetazolamide
Conditions: hypoxia

Overview

Phase 4, randomised, double-blind trial in hypoxia comparing Acetazolamide with Placebo (2 arms). Primary endpoint: Change in anterio-posterior sway velocity at Day 2. Started May 2018; status: completed.

Design

2 arms

Study design: RandomizedDouble-blind

Acetazolamide
Acetazolamide 375mg/day
Placebo
Placebo capsules

Who it enrols

Healthy Kyrgyz men and women aged 40-75 years living at low altitude (<800m), without respiratory or cardiovascular disease.

Endpoints

Primary

Change in anterio-posterior sway velocityDay 2

Secondary

Change in arterial oxygen saturationDay 2
Acute mountain sickness, severityDay 2
Change in cerebral tissue oxygenationDay 2
Change in muscle tissue oxygenationDay 2
AP sway velocity with and without study medicationDay 3

Beyond the preview

Go deeper on NCT03536429.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03536429.